Professor Timothy R. Hirst
Professor of Microbiology – Canberra, Australia
Tim has been the chairman of OzStar Therapeutics between 2012 and 2019. He has been instrumental in shaping a strong building block for OzStar Therapeutics. His invaluable contributions allowed OzStar Therapeutics to receive government grants and achieve world-wide issued patents. His tremendous contributions to the design of OzStar’s clinical trial allowed the company to succeed in its clinical goals. Tim is the chairman and CEO of GPN Gamma vaccines and other venture-backed companies.
Professor Anthony Barnett
Clinical Diabetes – Birmingham, United Kingdom
Professor Anthony Barnett (BSc, MD, FRCP) is Emeritus Professor of Medicine at The University of Birmingham and a Consultant Physician to one of the largest diabetes/endocrine units in the UK at the Heart of England NHS Foundation Trust, Birmingham. Prof Barnett has major research interests in genetics of diabetes and its microangiopathic complications, aetiology of diabetes vascular disease, pathogenesis of type 2 diabetes, new drugs for diabetes and its vascular complications and Health Service related issues including provision of diabetes care in the South Asian population.
Prof Barnett has published over 650 original papers and has edited major text books on diabetes as well as contributing to the Textbook of Diabetes, International Textbook of Diabetes and Encyclopaedia of Molecular Biology and Molecular Medicine. In 2011 Prof Barnett was awarded the Banting Memorial Lecture by Diabetes UK, its highest award to a person of international standing in diabetes research and in 2012 he was also given the South Asian Health Foundation & Lifetime Achievement award in recognition of his clinical and research work in diabetes in people of South Asian extraction. Prof Barnett has acted as an expert advisor to the UK National Institute for Health and Clinical Excellence (NICE), National Prescribing Centre and the Committee on Safety of Medicines. He also acted as an EASD representative advising the European Medicines Agency on diabetes related products.
Professor C. Ronald Kahn
Pre-Clinical and Clinical Diabetes – Boston, United States
Professor C. Ronald Kahn (MD) has played a leading role in diabetes research, including the discovery of glucagon-like peptide 1 – one of the best anti-diabetes injectable drugs in the global market. His current research encompasses insulin signal transduction and the mechanisms of insulin resistance in diabetes, obesity and metabolic syndrome. Prof Kahn is currently the Chief Academic Officer of the Joslin Diabetes Center and Pre-Clinical and Clinical Advisor to the company. From 2000-2007, Prof Kahn served as President of the Joslin Diabetes Center, and under his leadership, Joslin’s research grew more than 20-fold, with over 700 employees.
Prof Kahn is a founder of Metabio and Ember Therapeutics and has served on the scientific advisory boards of several biotech companies. He gained a medical degree from the University of Louisville and after training in internal medicine at Washington University, he moved to the NIH where he become the Head of the Section on Cellular and Molecular Physiology of NIDDK.
Professor Sanjoy K. Paul
Clinical Trial and Biostatistics – Brisbane, Australia
Professor Sanjoy Paul (MS, PhD) is an internationally recognised clinical trialist, biostatistician and a research administrator with long-standing experience of design and conduct of clinical trials and pharmaco- epidemiological studies in the fields of metabolic diseases. Prof. Paul’s current role is Head of the Clinical Trials and Biostatistics Unit (CTBU, www.qimr.edu.au/ctbu), based at the QIMR Berghofer Medical Research Institute, Australia. He also holds the Visiting Professorship of the Imperial College London, University of Warwick and University of Leicester. He has successfully built up highly productive collaborations with reputed international institutes and multinational pharmaceutical companies to design and conduct early and late phase clinical trials in the fields of auto-immune and metabolic diseases. Prof. Paul continues to play a pivotal role in the development of Australia’s translational research capabilities as one of the principal members of Therapeutic Innovation Australia. He also has the privilege of acting as an expert advisor to many clinical and non-clinical studies conducted by his international academic and industry collaborators.
Dr. Mustafa A. Noor
Endocrinologist – Boston, United States
Dr. Mustafa Noor (MD, FACP) is a Physician scientist / CMO with formal training in clinical research and 20 years of experience in all phases of clinical development. Board certified in internal medicine and endocrinology with clinical development experience in multiple therapeutic areas within large pharmaceutical and smaller biotech industry. Skilled in early to mid stage clinical development in multiple TAs and late stage in cardiometabolic and rare diseases. Experience also includes open innovation partnership and medical affairs and roles as interim CMO or CDO. Independent consultant for the last few years focusing on clinical development/regulatory strategy.
Professor Luis Vitetta
University of Queensland – Brisbane, Australia
Professor Luis Vitetta is currently an academic Professor with the University of Sydney, Faculty of Medicine and Health. Most recently (i.e., 2013–2022) he was the Director of Medical Research for Medlab Clinical Ltd in Sydney, and prior to that he was the Professor and Director of the Centre for Integrative Clinical and Molecular Medicine at the University of Queensland, Faculty of Medicine based at the Princess Alexandra Hospital and the Translational Research Institute.
He is a graduate from the University of Melbourne, Faculty of Medicine with expertise in clinical trial and epidemiology of chronic diseases with a research interest in the human microbiome, prebiotics and probiotic functional foods and pro-oxidant signaling cellular systems. He has received competitive and industry funding of approximately 5 million dollars over the period 2000–2023. He has a periodical record of 176 publications in various local and international journals with a Scopus H index of 40.
Mr. Roger Moore
International Business Development – Sydney, Australia
Mr. Roger Moore (BPharm) has over 40 years of experience in the international pharmaceutical business, including 30 years with Novo Nordisk. He established Novo in Japan in 1977 and retired as Chairman in 2007. He was Senior Vice President of the Japan and Oceania Region incl. Australia from 2000-2006, with sales turnover for the Region exceeding A$1 billion. In 2007 he received a knighthood from the Queen of Denmark for outstanding services to the state of Denmark especially in relation to Japan.
